GEPOTIDACIN MESYLATE - Generic Drug Details

What are the generic sources for gepotidacin mesylate and what is the scope of freedom to operate?

Gepotidacin mesylate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Gepotidacin mesylate has seventy-two patent family members in thirty-six countries.

One supplier is listed for this compound.

Summary for GEPOTIDACIN MESYLATE

International Patents:	72
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	8
DailyMed Link:	GEPOTIDACIN MESYLATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GEPOTIDACIN MESYLATE

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for GEPOTIDACIN MESYLATE

Drug Class	Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors Topoisomerase 2 Inhibitors Topoisomerase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for GEPOTIDACIN MESYLATE

J01XX	Other antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for GEPOTIDACIN MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230-001	Mar 25, 2025		RX	Yes	Yes	12,528,809		Y	Y
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230-001	Mar 25, 2025		RX	Yes	Yes	8,389,524		Y	Y
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230-001	Mar 25, 2025		RX	Yes	Yes	11,229,646
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230-001	Mar 25, 2025		RX	Yes	Yes
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230-001	Mar 25, 2025		RX	Yes	Yes
Glaxosmithkline	BLUJEPA	gepotidacin mesylate	TABLET;ORAL	218230-001	Mar 25, 2025		RX	Yes	Yes	10,702,521

International Patents for GEPOTIDACIN MESYLATE

Country	Patent Number	Title	Estimated Expiration
Japan	2023524427
European Patent Office	3639824
Costa Rica	20170069
Mexico	2009011317
Peru	20170501
Eurasian Patent Organization	015821

Market Dynamics and Financial Trajectory for Gepotidacin Mesylate

Last updated: March 5, 2026

Gepotidacin mesylate, a novel antibiotic developed by Johnson & Johnson's Janssen Pharmaceuticals, offers a new mechanism targeting bacterial infections resistant to existing antibiotics. Its unique mode of action—gathering bacterial DNA through a distinct pathway—positions it as a potential game-changer in addressing multi-drug resistant infections. The following provides an analysis of its market landscape, regulatory status, commercialization prospects, and financial outlook.

Market Landscape

Therapeutic Area and Unmet Needs

Gepotidacin targets uncomplicated urinary tract infections (uUTIs), complicated urinary tract infections (cUTIs), and gonorrhea. These indications address significant health issues:

• Urinary tract infections (UTIs): Affect an estimated 150 million people globally annually (Flores-Mireles et al., 2015).
• Gonorrhea: Estimated 87 million new cases worldwide in 2019 (WHO, 2021); rising resistance complicates treatment.

Resistance and Market Drivers

Antibiotic resistance escalates demand for new classes. Gepotidacin's novel mechanism offers effective options for resistant strains:

• It inhibits bacterial DNA gyrase and topoisomerase IV, similar to fluoroquinolones but with a different binding site, reducing cross-resistance.
• Regulatory agencies prioritize approvals for drugs addressing resistant infections; the CDC classifies ceftriaxone and azithromycin as facing increasing resistance.

Competitive Landscape

Gepotidacin faces competition from established antibiotics and emerging drugs:

Drug Class	Examples	Market Share	Resistance Profile
Fluoroquinolones	Ciprofloxacin, Levofloxacin	Dominant (complicated infections)	Rising resistance; significant adverse effects limit use
Macrolides	Azithromycin	Common for gonorrhea	Resistance increasing
New Antibiotics	Zoliflodacin, Solithromycin	Early-stage development	Differing mechanisms, early safety data

Regulatory Status

• Phase III Trials: Completed for uUTIs and uncomplicated gonorrhea.
• FDA Breakthrough Therapy Designation: Granted for gonorrhea in 2022, accelerating development.

Commercialization Challenges

• Competition with existing first-line antibiotics.
• Prescriber familiarity and antimicrobial stewardship guidelines.
• Cost considerations; price setting for novel antibiotics remains sensitive due to stewardship efforts.
• Market penetration depends on real-world efficacy, safety profile, and dosing convenience.

Financial Trajectory

R&D Investment

• Estimated total R&D costs surpass $1 billion since inception, typical for new antibiotics in advanced development stages.
• Investments include clinical trials, manufacturing scale-up, and regulatory expenses.

Revenue Projections

• The global antibiotic market estimated at $47 billion in 2022 (Persistence Market Research, 2022).
• Gepotidacin's potential market share (by 2030): 2-5% in its core indications.

Revenue Scenario	Year	Assumptions	Projected Revenue (USD millions)
Conservative	2024	Limited approval scope, initial uptake	$50–100
Moderate	2026	Expanded indications, broader adoption	$200–400
Optimistic	2030	Global use, high resistance-driven demand	$600–900

Pricing Strategy

• Given the strategic importance, price per treatment course may range from $200 to $1,000 depending on indication and compliance with stewardship policies.

Cost Structure

• Production costs estimated at 20-30% of sales.
• Marketing and commercialization expenses scale with sales volume, particularly in antibiotic stewardship frameworks that restrict overuse.

Profitability Outlook

• Break-even point projected between 2025 and 2027, assuming successful market entry and adoption.
• Post-approval, profit margins could hover around 25-30%, contingent on pricing, competition, and regulatory pressures.

Market Risks and Opportunities

Risks

• Rapid emergence of resistance against gepotidacin.
• Regulatory delays or denials if safety issues arise.
• Slow uptake due to established prescribing habits and stewardship constraints.

Opportunities

• First-in-class position for certain resistant infections.
• Expansion into new indications such as skin infections or intra-abdominal infections.
• Strategic licensing or partnerships to accelerate reach in emerging markets.

Key Takeaways

• Gepotidacin addresses significant unmet needs for resistant bacterial infections.
• Commercial success hinges on regulatory approval, safety profile, and clinical efficacy.
• Market penetration will depend on overcoming competition and stewardship constraints.
• Estimated revenue in the range of hundreds of millions USD by 2030 under optimistic scenarios.
• Costs are front-loaded in R&D; profitability likely after the drug gains substantial market acceptance.

FAQs

1. Will gepotidacin face resistance similar to fluoroquinolones?
It risks resistance development, but its distinct binding site reduces cross-resistance. Monitoring post-market resistance patterns is critical.

2. How fast can gepotidacin reach global markets?
Regulatory approval in key regions (US, EU, China) could occur by 2024-2025 if Phase III results are positive. Market access depends on pricing, formulary inclusion, and stewardship policies.

3. What are the main barriers to commercialization?
Prescriber adoption, antimicrobial stewardship frameworks, and resistance emergence are primary obstacles.

4. How does gepotidacin compare financially to existing antibiotics?
Pricing will be higher due to its novel status and resistance profile, but competitive pricing is necessary to gain market share under stewardship restrictions.

5. What strategic moves could enhance market penetration?
Partnering with regional distributors, expanding indications, and demonstrating durable efficacy and safety can support broader adoption.

---

References

1. Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology, 13(5), 269–284.
2. World Health Organization. (2021). Gonorrhea Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/gonorrhea
3. Persistence Market Research. (2022). Antibiotic Market—Scope and Forecast, 2022–2032.